ACTR-37. SHORT-TERM BEVACIZUMAB FOR RECURRENT GLIOBLASTOMAS. (5th November 2018) - Matsutani, Tomoo
Abstract: Survival benefit of bevacizumab (BEV) could not be confirmed for recurrent glioblastomas in EORTC 26101, while BEV is commonly chosen at recurrence due to its positive effect in daily life. BEV is usually repeated until tumor progression or adverse events, but the benefit of continuation of BEV is not known. Recently, short-term BEV has been administrated in our institute to avoid from adverse events, and to reduce medical costs. The survival data of the patients treated with short-term BEV are retrospectively analyzed. Thirty-two patients, who presented recurrence of primary glioblastoma, received short-term BEV, which is 10 mg/kg of BEV bi-weekly administration for 2–6 courses. BEV was discontinued after favorable response in MRI and social functioning, and was resumed for further progression. When the tumor progressed after short-term BEV, it was continued to delay neurological deterioration. Twenty-three of 32 patients could discontinue BEV in the first administration, and 13 of 23 patients were treated with second short-term BEV for further progression. Six of 13 could discontinue BEV again. In our retrospective cohort, median post-recurrent survival was 8.0 months, and 9- and 12-months survivals are 39.8% and 31.8%. The patients, who were able to discontinue BEV, showed statistically longer survival than the patients, who were not, 11.0 months and 3.5 months (p=0.0002, Log-rank). BEV could be safely discontinued for the patients, who respond well for the first administration, and the initial response to BEV might be a good prognostic factor at recurrence.